Initial results from the STAMPEDE trial of androgen deprivation therapy with and without celecoxib in patients with prostate cancer have shown that celecoxib does not confer benefit. Despite this negative finding, this multiarm, multistage trial will be informative of future clinical trial design, particularly as new agents become available for prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
James, N. D. et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 13, 549–558 (2012).
James, N. D. STAMPEDE. Systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy. A multi-arm multi-stage randomised controlled trial. STAMPEDE [online], (2011).
Schjerning Olsen, A. M. et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 120, 2226–2235 (2011).
Basler, J. W. & Piazza, G. A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J. Urol. 171, S59–S63 (2004).
Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873–884 (2006).
Smith, M. R. et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J. Clin. Oncol. 24, 2723–2728 (2006).
Hussain, M. et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 27, 2450–2456 (2009).
Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984–3990 (2006).
Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591–1597 (1999).
Studer, U. E. et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol. 24, 1868–1876 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
E. T. Lam has provided clinical trial support for Bristol–Myers Squibb and Genentech. T. W. Flaig has received research support from: Amgen, BN Immuno Therapeutics, Cougar, Dendreon, GTx, Medivation and Sanofi. He has also acted as a consultant for Sanofi and received honoraria from Amgen.
Rights and permissions
About this article
Cite this article
Lam, E., Flaig, T. Celecoxib trampled in the STAMPEDE trial. Nat Rev Urol 9, 358–360 (2012). https://doi.org/10.1038/nrurol.2012.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.112
